Nicorette patch reclassification
This article was originally published in The Tan Sheet
Executive SummaryThe Medicines and Healthcare products Regulatory Agency seeks to reclassify the Nicorette 16-hour, 25 mg patches from Pharmacy (P) status to General Sales List (GSL) status, according to an April 9 notice. MHRA says it is in the public interest to encourage smokers to use nicotine replacement therapy and this means "allowing smokers as much choice of NRT products as possible, and for greater convenience, making those products as widely available as possible." MHRA also says the safety profile and abuse potential of Nicorette patch is "not significantly different from other NRT formats." The patient information leaflet contains instructions on how to use and safely dispose of the patch, "thereby addressing any potential for misuse," MHRA says. Comments are due to the agency by May 7...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.